Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?
Trial Objectives
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
Who Can Participate
You may be able to join this study if you are at least 18 years old, with medically inoperable Stage I/IIA NSCLC and if you have not received prior anticancer therapy for lung cancer.
Age: 18+ Gender: Any
Estimated Time Commitment
Up to 7 years
Time Commitment Details
If you are eligible and choose to be in the study, your participation will last up to 7 years. You will be asked to visit the study site about 26 times.
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Merck Sharp & Dohme Corp.
Principal Investigators
Laurie L. Carr, MD
Co-Investigators
Jeffrey Kern, MD